Synthesis and Antitumor Activity of Novel 5- and 6-Substituted Indazole Derivatives

doi:10.6023/cjoc202107049

Abstract

In order to search for new antitumor drugs with high efficiency and low toxicity, 5- and 6-substituted indazole compounds were designed and synthesized. The antiproliferative activity of target compounds in four human cancer cells, PC-3 (human prostate cancer cell), MCF-7 (human breast cancer cell), HepG-2 (human hepatoma cell) and MGC-803 (human gastric cancer cell), was evaluated by thiazole blue (MTT) method. The results showed that most of the compounds had specific antiproliferative activity against PC-3. Among them, N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1-isopropyl-1H-in- doleazole-5-carboxyamide (8a) and N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1-isopropyl-1H-indoleazole-6-formamide (14a) possess strong antitumor activity against PC-3 with IC₅₀ values of 6.21 and 6.43 μmol/L, respectively. It provides a new idea for the research of anti-tumor drugs for prostate cancer.

Key words: indazole, cancer, antiproliferative activity, prostatic cancer

Cite this article

Yaquan Cao, Yingxue Yang, Hongjin Zhai, Jin Wang, Shuo Zhang, Huanhuan Wang, Pu Yang, Chunli Wu. Synthesis and Antitumor Activity of Novel 5- and 6-Substituted Indazole Derivatives[J]. Chinese Journal of Organic Chemistry, 2022, 42(2): 590-599.

Export EndNote|Reference Manager|ProCite|BibTeX|RefWorks

share this article

Fig. & Tab. 8

References 21

[1]	https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/
[2]	Xu, K. M.; Chen, R. C.; Schuster, D. M.; Jani, A. B. Urol. Oncol. 2019, 37, 611. doi: 10.1016/j.urolonc.2019.04.008
[3]	Zhang, X.; Zhu, Y.; Dong, S.; Zhang, Lu, A.; Li, Y. Y.; Lv, S.; Zhang, J. Life Sci. 2019, 232, 116526. doi: 10.1016/j.lfs.2019.06.001
[4]	Li, J. Y.; Qiao, S.; Li, Y. J.; Wang, J.; Liu, W.; Pan, W. S. Int. J. Biol. Macromol. 2019, 134, 63. doi: 10.1016/j.ijbiomac.2019.05.031
[5]	Zhang, Y.; Rong, D.; Li, B.; Wang, Y. J. Med. Chem. 2021, 64, 7900. doi: 10.1021/acs.jmedchem.0c02055 pmid: 33599482
[6]	Cao, Y.; Luo, C.; Yang, P.; Li, P.; Wu, C. Med. Chem. Res. 2020, 30, 501. doi: 10.1007/s00044-020-02665-7
[7]	Fabian, L. V.; Lilian, Y. M.; Josel, M. F. J. Biomol. Screen. 2011, 16, 862. doi: 10.1177/1087057111414902
[8]	Tzvetkov, N. T.; Hinz, S.; Küppers, P.; Gastreich, M.; Müller, C. E. J. Med. Chem. 2014, 57, 6679. doi: 10.1021/jm500729a pmid: 24955776
[9]	Zhou, J.; Goh, B. C.; Albert, D. H.; Chen, C. S. J. Hematol. Oncol. 2009, 2, 33. doi: 10.1186/1756-8722-2-33
[10]	Cainap, C.; Qin, S.; Huang, W.-T.; Chung, I. J.; Pan, H.; Cheng, Y.; Kudo, M.; Kang, Y.-K.; Chen, P.-J.; Toh, H.-C.; Gorbunova, V.; Eskens, F. A. L. M.; Qian, J.; McKee, M. D.; Ricker, J. L.; Carlson, D. M.; El-Nowiem, S. J. Clin. Oncol. 2015, 33, 172. doi: 10.1200/JCO.2013.54.3298 pmid: 25488963
[11]	Bellesoeur, A.; Carton, E.; Alexandre, J.; Goldwasser, F.; Huillard, O. Drug Des.,Dev. Ther. 2017, 11, 2801. doi: 10.2147/DDDT
[12]	Keating, G. M. Drugs 2015, 75, 1903. doi: 10.1007/s40265-015-0483-x
[13]	Yoshida, K.; Takagi, T.; Kondo, T.; Kobayashi, H.; Iizuka, J.; Fukuda, H.; Ishihara, H.; Okumi, M.; Ishida, H.; Tanabe, K. Jpn. J. Clin. Oncol. 2019, 49, 576. doi: 10.1093/jjco/hyz040
[14]	Chakrapani, C.; Muniappan, M. J. Clin. Diagn. Res. 2016, 10, 01.
[15]	Wong, T. W.; Lee, F. Y.; Yu, C.; Luo, F. R.; Oppenheimer, S.; Zhang, H.; Smykla, R. A.; Mastalerz, H.; Fink, B. E.; Hunt, J. T.; Gavai, A. V.; Vite, G. D. Clin. Can. Res. 2006, 12, 6186. doi: 10.1158/1078-0432.CCR-06-0642
[16]	Soria, J. C.; Massard, C.; Armand, J.-P.; Andreis, D. D.; Ropert, S.; Lopez, E.; Catteau, A.; James, J.; Marier, J.-F.; Beliveau, R. E. M. J. B. M. Ann. Oncol. 2012, 23, 463. doi: 10.1093/annonc/mdr137 pmid: 21576284
[17]	Kuntz, K. W.; Campbell, J. E.; Keilhack, H.; Pollock, R. M.; Knutson, S. K.; Porter-Scott, M.; Richon, V. M.; Sneeringer, C. J.; Wigle, T. J.; Allain, C. J.; Majer, C. R.; Moyer, M. P.; Copeland, R. A.; Chesworth, R. J. Med. Chem. 2016, 59, 1556. doi: 10.1021/acs.jmedchem.5b01501
[18]	Li, M.; Zheng, N.; Li, J.; Zheng, Y.; Song, W. Green Chem. 2020, 22, 2394. doi: 10.1039/D0GC00555J
[19]	Worrell, J. A. M. B. T.; Fokin, V. V. Science 2013, 340, 457. doi: 10.1126/science.1229506 pmid: 23558174
[20]	Yup, S.; Bae, S.; Seong, D.; Hyung, W.WO 2014/129796, 2014.
[21]	Claudia, F.; Antonella, P.; Yeong, S. K.; Sunmin, L.; Andrea, G.; Marco, D. P.; Anna, T.; Alice, Z.; Michela, C.; Nadia, Z.; Michelandrea, D. C. J. Med. Chem. 2017, 60, 3082. doi: 10.1021/acs.jmedchem.7b00105 pmid: 28272894

Compound	R	IC₅₀^a/(μmol•L^–1)
Compound	R	PC-3	MCF-7	HepG-2	MGC-803
7a	H	30.67±1.63	>40	>40	>40
7b	2,4-(CH₃)₂	>40	>40	>40	>40
7c	3,4-(CH₃)₂	>40	>40	>40	>40
7d	4-I	39.63±1.21	>40	>40	>40
7e	4-F	38.72±0.96	>40	>40	>40
7f	3-Br	36.21±0.87	>40	>40	>40
7g	3-F	38.14±1.03	>40	>40	>40
7h	4-NO₂	>40	>40	>40	>40
7i	4-CH₃	36.98±1.63	>40	>40	>40
7j	3-CH₃	34.55±1.14	26.12±0.78	>40	34.75±2.07
7k	2-CH₃	35.40±2.97	>40	>40	>40
7l	2-F	>40	>40	>40	>40
7m	4-CF₃	37.21±0.89	>40	>40	>40
7n	4-CH₂CH₃	31.05±0.95	>40	>40	>40
7o	4-OCH₃	>40	>40	>40	>40
8a	H	6.21±0.84	19.33±0.68	18.17±2.91	20.56±1.01
8b	4-CF₃	15.81±0.78	>40	>40	>40
8c	4-CN	9.53±0.62	19.26±1.23	30.04±1.89	20.06±1.80
8d	4-OCH₃	28.20±2.20	>40	>40	>40
8e	4-C(CH₃)₃	8.76±1.98	>40	>40	>40
5-Fu^b	—	8.41±0.92	15.14±0.44	11.68±0.48	10.14±0.89

Compound	R	IC₅₀^a/(μmol•L^–1)
Compound	R	PC-3	MCF-7	HepG-2	MGC-803
7a	H	30.67±1.63	>40	>40	>40
7b	2,4-(CH₃)₂	>40	>40	>40	>40
7c	3,4-(CH₃)₂	>40	>40	>40	>40
7d	4-I	39.63±1.21	>40	>40	>40
7e	4-F	38.72±0.96	>40	>40	>40
7f	3-Br	36.21±0.87	>40	>40	>40
7g	3-F	38.14±1.03	>40	>40	>40
7h	4-NO₂	>40	>40	>40	>40
7i	4-CH₃	36.98±1.63	>40	>40	>40
7j	3-CH₃	34.55±1.14	26.12±0.78	>40	34.75±2.07
7k	2-CH₃	35.40±2.97	>40	>40	>40
7l	2-F	>40	>40	>40	>40
7m	4-CF₃	37.21±0.89	>40	>40	>40
7n	4-CH₂CH₃	31.05±0.95	>40	>40	>40
7o	4-OCH₃	>40	>40	>40	>40
8a	H	6.21±0.84	19.33±0.68	18.17±2.91	20.56±1.01
8b	4-CF₃	15.81±0.78	>40	>40	>40
8c	4-CN	9.53±0.62	19.26±1.23	30.04±1.89	20.06±1.80
8d	4-OCH₃	28.20±2.20	>40	>40	>40
8e	4-C(CH₃)₃	8.76±1.98	>40	>40	>40
5-Fu^b	—	8.41±0.92	15.14±0.44	11.68±0.48	10.14±0.89

Compound	R	IC₅₀^a/(μmol•L^–1)
Compound	R	PC-3	MCF-7	HepG-2	MGC-803
13a	H	30.25±1.36	>40	>40	>40
13b	2,4-(CH₃)₂	>40	>40	>40	>40
13c	3,4-(CH₃)₂	>40	>40	>40	>40
13d	4-I	38.37±0.89	>40	>40	>40
13e	4-F	38.67±0.67	>40	>40	>40
13f	3-Br	31.51±1.76	>40	>40	>40
13g	3-F	37.69±0.96	>40	>40	>40
13h	4-NO₂	>40	>40	>40	>40
13i	4-CH₃	32.05±1.35	>40	>40	>40
13j	3-CH₃	31.65±1.08	>40	>40	>40
13k	2-CH₃	30.15±1.25	>40	>40	>40
13l	2-F	>40	>40	>40	>40
13m	4-CF₃	36.28±0.87	>40	>40	>40
13n	4-CH₂CH₃	30.26±0.58	>40	>40	>40
13o	4-OCH₃	>40	>40	>40	>40
14a	H	6.43±0.80	11.19±0.40	12.72±0.60	14.41±2.12
14b	4-CF₃	21.90±1.69	31.91±1.18	30.99±0.99	39.92±1.63
14c	4-CN	11.16±1.76	32.28±0.79	24.71±3.90	33.06±2.68
14d	4-OCH₃	34.74±1.27	>40	>40	>40
14e	4--C(CH₃)₃	12.82±0.71	>40	>40	>40
5-Fu^b	—	8.41±0.92	15.14±0.44	11.68±0.48	10.14±0.89

Compound	R	IC₅₀^a/(μmol•L^–1)
Compound	R	PC-3	MCF-7	HepG-2	MGC-803
13a	H	30.25±1.36	>40	>40	>40
13b	2,4-(CH₃)₂	>40	>40	>40	>40
13c	3,4-(CH₃)₂	>40	>40	>40	>40
13d	4-I	38.37±0.89	>40	>40	>40
13e	4-F	38.67±0.67	>40	>40	>40
13f	3-Br	31.51±1.76	>40	>40	>40
13g	3-F	37.69±0.96	>40	>40	>40
13h	4-NO₂	>40	>40	>40	>40
13i	4-CH₃	32.05±1.35	>40	>40	>40
13j	3-CH₃	31.65±1.08	>40	>40	>40
13k	2-CH₃	30.15±1.25	>40	>40	>40
13l	2-F	>40	>40	>40	>40
13m	4-CF₃	36.28±0.87	>40	>40	>40
13n	4-CH₂CH₃	30.26±0.58	>40	>40	>40
13o	4-OCH₃	>40	>40	>40	>40
14a	H	6.43±0.80	11.19±0.40	12.72±0.60	14.41±2.12
14b	4-CF₃	21.90±1.69	31.91±1.18	30.99±0.99	39.92±1.63
14c	4-CN	11.16±1.76	32.28±0.79	24.71±3.90	33.06±2.68
14d	4-OCH₃	34.74±1.27	>40	>40	>40
14e	4--C(CH₃)₃	12.82±0.71	>40	>40	>40
5-Fu^b	—	8.41±0.92	15.14±0.44	11.68±0.48	10.14±0.89

Compd.	IC₅₀^a/(μmol•L^–1)		Active ratio
Compd.	PC-3	WPYM-1	WPYM-1/PC-3
8a	6.21±0.84	27.07±1.36	4.35
14a	6.43±0.80	23.57±1.77	3.67

新型5位与6位取代的吲唑类衍生物的合成及抗肿瘤活性研究